Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Integer Holdings shares dip 3% as revenue guidance falls short of consensus

EditorRachael Rajan
Published 25/04/2024, 13:52
© Reuters.

PLANO, Texas - Integer Holdings Corporation (NYSE:ITGR) reported a solid start to the first quarter of 2024, with sales and adjusted EPS figures slightly surpassing analyst expectations. However, the company's stock fell 3% premarket as its full-year revenue outlook came in below the consensus estimate.

For the first quarter ended March 29, 2024, Integer posted sales of $415 million, a 10% increase from $378.8 million in the first quarter of the previous year, and a notch above the consensus estimate of $412.8 million. Adjusted EPS for the quarter was $1.14, beating the analyst estimate by $0.02 and marking a substantial increase from $0.87 in the same period last year.

Joseph Dziedzic, Integer's president and CEO, highlighted the company's strong start, with sales growing 10% YoY and adjusted operating income growing 26%. He reiterated the company's financial outlook for 2024, expecting sales growth of 9% to 11% and adjusted operating income growth of 13% to 20%.

Despite the positive performance in the first quarter, Integer's full-year revenue guidance of $1.73 to $1.77 billion fell short of the consensus estimate of $1.76 billion. The midpoint of the guidance range, $1.75 billion, is below the analyst consensus, prompting a negative market response. The company's EPS guidance for FY2024 is set at $5.01 to $5.43, with the midpoint slightly below the consensus of $5.31.

The company's financial strength was further demonstrated by a 57% increase in GAAP net income to $21 million and a 33% increase in non-GAAP adjusted net income to $39 million compared to the first quarter of the previous year. GAAP operating income rose 15% to $39 million, while non-GAAP adjusted operating income saw a 26% increase to $63 million. Adjusted EBITDA also grew by 22% to $81 million.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The growth in sales was primarily driven by a 16% increase in Cardio & Vascular sales, an 8% rise in Cardiac Rhythm Management & Neuromodulation sales, and a 4% growth in Advanced Surgical, Orthopedics & Portable Medical sales. However, Electrochem sales saw a decrease compared to the first quarter of the previous year.

Dziedzic stated, "Integer started the year strong with first quarter 2024 sales growing 10% versus a year ago and adjusted operating income growing 26%, more than two and a half times the rate of sales growth."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.